A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
- Conditions
- Advanced or Metastatic Non-small Cell Lung Cancer
- Interventions
- Registration Number
- NCT05388669
- Lead Sponsor
- Janssen Research & Development, LLC
- Brief Summary
The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantamab, amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), for subcutaneous administration. This formulation has the potential to enhance both the patient and physician experience with amivantamab by providing easier and accelerated administration.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 418
- Have histologically or cytologically confirmed, advanced or metastatic non-small cell lung cancer (NSCLC), characterized by either epidermal growth factor receptor (EGFR) Exon 19 deletion (Exon 19del) or Exon 21 leucine 858 to arginine substitution (Exon 21 L858R) mutation by an Food and Drug Administration (FDA)-approved or other validated test of either circulating tumor deoxyribonucleic acid (ctDNA) or tumor tissue in a clinical laboratory improvement amendments (CLIA) certified laboratory (sites in the United Started [US]) or an accredited local laboratory (sites outside of the US)
- Have progressed on or after osimertinib (or another approved 3rd generation epidermal growth factor receptor [EGFR] tyrosine kinase inhibitor [TKI]) and platinum-based chemotherapy (irrespective of order). a) The 3rd generation EGFR TKI must have been administered as the first EGFR TKI for metastatic disease or as the second TKI after prior treatment with first- or second-generation EGFR TKI in participants with metastatic EGFR T790M mutation positive NSCLC. b) Participants who decline or are otherwise ineligible for chemotherapy may be enrolled after discussion with the medical monitor. c) Any adjuvant or neoadjuvant treatment, whether with a 3rd generation EGFR TKI or platinum based chemotherapy, would count towards the prior treatment requirement if the participant experienced disease
- Have at least 1 measurable lesion, according to response evaluation criteria in solid tumors (RECIST) version 1.1
- Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1
- Any toxicities from prior anticancer therapy must have resolved to common terminology criteria for adverse events (CTCAE) Version 5.0 Grade 1 or baseline level (except for alopecia [any grade], Grade less than or equal to (<=) 2 peripheral neuropathy, and Grade <=2 hypothyroidism stable on hormone replacement)
- Participant has received cytotoxic, investigational, or targeted therapies beyond one regimen of platinum-based chemotherapy and EGFR inhibitors
- Participant has received radiotherapy for palliative purposes less than 7 days prior to randomization
- Participant has symptomatic or progressive brain metastases
- Participant has leptomeningeal disease, or participant has spinal cord compression not definitively treated with surgery or radiation
- Participant has uncontrolled tumor-related pain
- Participant has a medical history of interstitial lung disease (ILD), including drug-induced ILD or radiation pneumonitis
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm B: Lazertinib with Amivantamab Intravenous (IV) Infusion Amivantamab Intravenous Lazertinib 240 mg will be administered orally once. Participants will receive amivantamab, 1050 mg or 1400 mg depending on the body weight as an IV infusion. Participants benefiting from study treatment after primary analysis may continue to receive access to study treatment within the study by transferring to the LTE Phase. Arm A: Lazertinib with Amivantamab SC-CF Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF) Lazertinib 240 milligrams (mg) will be administered orally once daily. Participants will receive amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), 1600 mg/ 2240 mg depending on the body weight by manual injection. Participants benefiting from study treatment after primary analysis may continue to receive access to study treatment within the study by transferring to the long-term extension (LTE) Phase. Arm B: Lazertinib with Amivantamab Intravenous (IV) Infusion Lazertinib Lazertinib 240 mg will be administered orally once. Participants will receive amivantamab, 1050 mg or 1400 mg depending on the body weight as an IV infusion. Participants benefiting from study treatment after primary analysis may continue to receive access to study treatment within the study by transferring to the LTE Phase. Arm A: Lazertinib with Amivantamab SC-CF Lazertinib Lazertinib 240 milligrams (mg) will be administered orally once daily. Participants will receive amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), 1600 mg/ 2240 mg depending on the body weight by manual injection. Participants benefiting from study treatment after primary analysis may continue to receive access to study treatment within the study by transferring to the long-term extension (LTE) Phase.
- Primary Outcome Measures
Name Time Method For All Regions Other Than the European Union (EU) and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State on Cycle 4 Day 1 Cycle 4 Day 1 (28 days cycle) Ctrough is the observed serum concentration of Amivantamab at steady state on Cycle 4 Day 1 immediately prior to the next drug administration.
For EU and Any Applicable Region: Observed Serum Concentration (Ctrough) of Amivantamab at Pre-dose on Cycle 2 Day 1 Cycle 2 Day 1 (28 days cycle) Ctrough is the observed serum concentration of Amivantamab at pre-dose on Cycle 2 Day 1 immediately prior to the next drug administration.
Area Under the Concentration Time Curve from Day 1 to Day 15 (AUC[Day 1-15]) of Amivantamab of Cycle 2 Cycle 2 Day 1 to Cycle 2 Day 15 (28 days cycle) AUC(Day 1-15) defined as area under the concentration time curve from Cycle 2 Day 1 to Day 15, will be reported.
- Secondary Outcome Measures
Name Time Method Objective Response Rate (ORR) Up to 1 year 11 months ORR is defined as the percentage of participants who achieve either a CR or PR as per Response Evaluation Criteria In Solid Tumors Criteria (RECIST version 1.1).
Progression-Free Survival (PFS) Up to 1 year 11 months PFS is defined as the time from randomization until the date of objective disease progression or death, whichever comes first, based on RECIST version 1.1.
Duration of Response (DOR) Up to 1 year 11 months The DoR is defined as the time from the date of first documented response (PR or CR) until the date of documented progression or death, whichever comes first, for participants who have PR or CR.
Time to Response (TTR) Up to 1 year 11 months Time to response (that is time to first response) is defined as the time from the date of randomization to the date of first documentation of a response (PR or CR) prior to any disease progression and subsequent anticancer therapy, as defined by BICR using RECIST version 1.1., for participants who have PR or CR as their best response.
Number of Participants With Adverse Events (AEs) Up to 4 year 11 months An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the intervention. This outcome includes participants continuing in the LTE Phase for whom, after the primary analysis, data were collected until a discontinuation criterion is met, or until 3 years after local marketing authorization is obtained.
Number of Participants with AEs by Severity Up to 4 year 11 months Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. This outcome includes participants continuing in the LTE Phase for whom, after the primary analysis, data were collected until a discontinuation criterion is met, or until 3 years after local marketing authorization is obtained.
Number of Participants with Clinical Laboratory Abnormalities Up to 4 year 11 months Number of participants with clinical laboratory abnormalities (serum Chemistry, hematology, coagulation, and urinalysis) will be reported. This outcome includes participants continuing in the LTE Phase for whom, after the primary analysis, data were collected until a discontinuation criterion is met, or until 3 years after local marketing authorization is obtained.
Number of Participants with Clinical Laboratory Abnormalities by Severity Up to 4 year 11 months Number of participants with clinical laboratory abnormalities by severity (serum Chemistry, hematology, coagulation, and urinalysis) will be reported. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. This outcome includes participants continuing in the LTE Phase for whom, after the primary analysis, data were collected until a discontinuation criterion is met, or until 3 years after local marketing authorization is obtained.
Number of Participants Infusion Related Reactions (IRRs) Up to 1 year 11 months Number of participants with IRRs will be reported.
Number of Participants with Infusion Related Reactions (IRRs) by Severity Up to 1 year 11 months Number of participants with IRRs by severity will be reported.
For All Regions Other Than the EU and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Pre-dose on Cycle 2 Day 1 Cycle 2 Day 1 (28 days cycle) The Ctrough is the observed serum concentration of Amivantamab at pre-dose on Cycle 2 Day 1 immediately prior to the next drug administration.
For EU and Any Applicable Region: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State on Cycle 4 Day 1 Cycle 4 Day 1 (28 days cycle) The Ctrough is the observed serum concentration of Amivantamab at steady state on Cycle 4 Day 1 immediately prior to the next drug administration.
Model-Predicted Area Under the Concentration Time Curve from Day 1 to Day 15 (AUC[Day 1-15]) of Amivantamab at Steady State of Cycle 4 From Cycle 4 Day 1 to Cycle 4 Day 15 (28 days cycle) Model-predicted AUC(Day 1-15) defined as area under the concentration time curve from Cycle 4 Day 1 to Day 15, will be reported.
Percentage of Participants with Presence of Anti-amivantamab Antibodies and Anti-rHuPH20 Antibodies Up to 1 year 11 months Percentage of participants with presence of anti-amivantamab antibody anti-rHuPH20 antibodies will be reported.
Percentage of Participants with Cancer Therapy Satisfaction as Assessed by Therapy Administration Satisfaction Questionnaire (TASQ) Up to 1 year 11 months Percentage of participants with cancer therapy satisfaction in will be assessed using the modified TASQ. The modified TASQ is an 11-item questionnaire measuring the impact of each mode of treatment administration on five domains: Physical Impact, Psychological Impact, Impact on Activities of Daily Living, Convenience, and Satisfaction.
Change from Baseline in TASQ as Assessed Over Time Up to 1 year 11 months Change from baseline in TASQ as assessed Over time will be reported. The modified TASQ is an 11-item questionnaire measuring the impact of each mode of treatment administration on five domains: Physical Impact, Psychological Impact, Impact on Activities of Daily Living, Convenience, and Satisfaction.
Participant Chair Time Up to 1 year 11 months Participant chair time will be assessed by time and motion analysis.
Duration of Treatment Administration Up to 1 year 11 months Duration of treatment administration will be assessed by time and motion analysis.
Active HCP Time For Drug Preparation, Treatment Administration and Posttreatment Monitoring Up to 1 year 11 months Active health care professional time for drug preparation, treatment administration, and posttreatment monitoring will be assessed by time and motion analysis.
Participant Time in Treatment Room Up to 1 year 11 months Participant time in treatment room will be assessed by time and motion analysis.
Trial Locations
- Locations (187)
Hosp. Univ. Insular de Gran Canaria
🇪🇸Las Palmas de Gran Canaria, Spain
Hosp. Univ. Lucus Augusti
🇪🇸Lugo, Spain
Hosp. Gral. Univ. Gregorio Maranon
🇪🇸Madrid, Spain
Hosp. Univ. La Paz
🇪🇸Madrid, Spain
Hosp. Univ. Pta. de Hierro Majadahonda
🇪🇸Majadahonda, Spain
Hosp Regional Univ de Malaga
🇪🇸Málaga, Spain
Hosp. Univ. Central de Asturias
🇪🇸Oviedo, Spain
Hosp. Univ. Son Espases
🇪🇸Palma de Mallorca, Spain
Hosp. Virgen Del Rocio
🇪🇸Sevilla, Spain
Hosp. Univ. I Politecni La Fe
🇪🇸Valencia, Spain
Changhua Christian Hospital
🇨🇳Changhua, Taiwan
Chang Kung Memorial Hospital
🇨🇳Kaohsiung City, Taiwan
Kaohsiung Medical University Chung Ho Memorial Hospital
🇨🇳Kaohsiung, Taiwan
Chung Shan Medical University Hospital
🇨🇳Taichung, Taiwan
Cancer Research SA
🇦🇺Adelaide, Australia
Universitaetsklinikum Giessen und Marburg GmbH
🇩🇪Giessen, Germany
Munster University Hospital
🇩🇪Münster, Germany
Oncologianova GmbH
🇩🇪Recklinghausen, Germany
Onkologische Schwerpunktpraxis
🇩🇪Weinsberg, Germany
Rambam Medical Center
🇮🇱Haifa, Israel
Hosp Reina Sofia
🇪🇸Córdoba, Spain
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
🇨🇳Hangzhou, China
Centrum Onkologii im Prof F Lukaszczyka w Bydgoszczy
🇵🇱Bydgoszcz, Poland
City of Hope Duarte
🇺🇸Duarte, California, United States
City of Hope Orange County Lennar Foundation Cancer Center
🇺🇸Irvine, California, United States
City of Hope Long Beach Elm
🇺🇸Long Beach, California, United States
National Jewish Health
🇺🇸Denver, Colorado, United States
Baptist Lynn Cancer Institute
🇺🇸Boca Raton, Florida, United States
Orlando Health
🇺🇸Orlando, Florida, United States
University of Kansas
🇺🇸Kansas City, Kansas, United States
University of Michigan
🇺🇸Ann Arbor, Michigan, United States
Astera Cancer Care
🇺🇸East Brunswick, New Jersey, United States
Rutgers Cancer Institute of New Jersey
🇺🇸New Brunswick, New Jersey, United States
Montefiore Medical Center
🇺🇸Bronx, New York, United States
NYU Langone Health Laura and Isaac Perlmutter Cancer Center
🇺🇸New York, New York, United States
Providence Portland Medical Center
🇺🇸Portland, Oregon, United States
Providence Oncology and Hematology Care Clinic Westside
🇺🇸Portland, Oregon, United States
University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine
🇺🇸Philadelphia, Pennsylvania, United States
Medical University of South Carolina
🇺🇸Charleston, South Carolina, United States
Virginia Cancer Specialists
🇺🇸Fairfax, Virginia, United States
CEMIC (Centro de Educación Médica e Investigaciones Clínicas)
🇦🇷Buenos Aires, Argentina
IADT Instituto Argentino de Diagnostico y Tratamiento
🇦🇷Caba, Argentina
Centro Oncológico Korben
🇦🇷Ciudad Autonoma de Buenos Aires, Argentina
Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
🇦🇷Cordoba, Argentina
Sanatorio Allende
🇦🇷Cordoba, Argentina
Clínica Viedma
🇦🇷Viedma, Argentina
Chris O'Brien Lifehouse
🇦🇺Camperdown, Australia
Peter MacCallum Cancer Centre
🇦🇺Melbourne, Australia
St John of God Hospital Murdoch
🇦🇺Murdoch, Australia
Westmead Hospital
🇦🇺Westmead, Australia
Princess Alexandra Hospital
🇦🇺Woolloongabba, Australia
Fundacao Pio XII
🇧🇷Barretos, Brazil
Cetus Oncologia
🇧🇷Belo Horizonte, Brazil
Instituto Cionc de Ensino e Pesquisa S/S
🇧🇷Curitiba, Brazil
Ynova Pesquisa Clinica
🇧🇷Florianopolis, Brazil
Fundacao Sao Francisco Xavier HMC Unidade de Oncologia
🇧🇷Ipatinga, Brazil
UPCO Unidade de Pesquisa Clinica em Oncologia
🇧🇷Pelotas, Brazil
Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS
🇧🇷Porto Alegre, Brazil
Impar Servicos Hospitalares S/A
🇧🇷Rio de Janeiro, Brazil
Oncoclinicas Rio de Janeiro S A
🇧🇷Rio de Janeiro, Brazil
Instituto D Or de Pesquisa e Ensino IDOR
🇧🇷Rio de Janeiro, Brazil
Nucleo de Oncologia da Bahia
🇧🇷Salvador, Brazil
CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia
🇧🇷Santo Andre, Brazil
Impar Servicos Hospitalares SA Hospital Nove de Julho
🇧🇷Sao Paulo, Brazil
Onco Star SP Oncologia Ltda
🇧🇷Sao Paulo, Brazil
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
🇧🇷Sao Paulo, Brazil
Núcleo de Pesquisa São Camilo
🇧🇷São Paulo, Brazil
The Ottawa Hospital Cancer Centre
🇨🇦Ottawa, Ontario, Canada
Princess Margaret Hospital
🇨🇦Toronto, Ontario, Canada
Beijing Shijitan Hospital, Capital Medical University
🇨🇳Beijing, China
Beijing Friendship Hospital Capital Medical University
🇨🇳Beijing, China
Peking University Third Hospital
🇨🇳Beijing, China
Beijing Chest hospital, Capital medical university
🇨🇳Beijing, China
Cancer Hospital Chinese Academy of Medical Sciences
🇨🇳Beijing, China
Jilin cancer hospital
🇨🇳Changchun, China
The First People's Hospital Of Changzhou
🇨🇳Changzhou, China
Sichuan Cancer Hospital
🇨🇳Chengdu, China
West China Hospital Sichuan University
🇨🇳Chengdu, China
Chongqing University Cancer Hospital
🇨🇳Chongqing, China
Southwest Hospital
🇨🇳ChongQing, China
First Affiliated Hospital of Gannan Medical University
🇨🇳Ganzhou, China
The First Affiliated Hospital Sun Yat sen University
🇨🇳Guang Zhou, China
Sun Yat-Sen Memorial Hospital Sun Yat-sen University
🇨🇳Guangzhou, China
Zhejiang Cancer Hospital
🇨🇳Hang Zhou, China
The Second Affiliated Hospital of Zhejiang University College of Medicine
🇨🇳Hangzhou, China
Harbin medical university cancer hospital
🇨🇳Harbin, China
Huizhou Municipal Central Hospital
🇨🇳Huizhou, China
Huizhou First Hospital
🇨🇳Huizhou, China
Liuzhou people's Hospital
🇨🇳Liuzhou, China
Affiliated Hospital of North Sichuan Medical College
🇨🇳Nanchong, China
Fudan University Shanghai Cancer Center
🇨🇳Shanghai, China
Shenzhen People s Hospital
🇨🇳Shen Zhen Shi, China
Shengjing Hospital Of China Medical University
🇨🇳Shenyang, China
Shenzhen university General Hospital
🇨🇳Shenzhen, China
Tianjin Medical University Cancer Institute and Hospital
🇨🇳Tianjin, China
Union Hospital Tongji Medical College of Huazhong University of Science and Technology
🇨🇳Wuhan, China
The First Affiliated Hospital of Xian Jiaotong University
🇨🇳XI An, China
Xiangyang Central Hospital
🇨🇳Xiangyang, China
Yantai Yuhuangding Hospital
🇨🇳Yantai, China
Henan Cancer Hospital
🇨🇳Zhengzhou, China
CHU Grenoble
🇫🇷La Tronche, France
Institute Coeur Poumon
🇫🇷Lille, France
CHU de Limoges Hopital Dupuytren
🇫🇷Limoges, France
Hopital Nord
🇫🇷Marseille Cedex 20, France
Evangelische Lungenklinik Berlin
🇩🇪Berlin, Germany
Niels-Stensen-Kliniken Franziskus-Hospital Harderberg
🇩🇪Georgsmarienhütte, Germany
Shaare Zedek Medical Center
🇮🇱Jerusalem, Israel
Meir Medical Center
🇮🇱Kfar Saba, Israel
Rabin Medical Center
🇮🇱Petah-Tikva, Israel
Chaim Sheba Medical Center
🇮🇱Ramat Gan, Israel
Oncologia Medica - Irccs - Istituto Tumori Giovanni Paolo II
🇮🇹Bari, Italy
A O U Sant Orsola Malpighi
🇮🇹Bologna, Italy
European Institute of Oncology
🇮🇹Milano, Italy
Aou San Luigi Gonzaga
🇮🇹Orbassano, Italy
Istituto Oncologico Veneto - IRCCS
🇮🇹Padova, Italy
Ospedale S. Maria Delle Croci
🇮🇹Ravenna, Italy
A.O. San Camillo Forlanini
🇮🇹Roma, Italy
Istituto Nazionale Tumori Regina Elena
🇮🇹Rome, Italy
Istituto Clinico Humanitas
🇮🇹Rozzano, Italy
National Cancer Center Hospital
🇯🇵Chuo Ku, Japan
National Hospital Organization Himeji Medical Center
🇯🇵Himeji, Japan
Kansai Medical University Hospital
🇯🇵Hirakata, Japan
Kanagawa Cancer Center
🇯🇵Kanagawa, Japan
Kurashiki Central Hospital
🇯🇵Kurashiki, Japan
Kurume University Hospital
🇯🇵Kurume, Japan
Matsusaka Municipal Hospital
🇯🇵Matsusaka, Japan
Niigata Cancer Center Hospital
🇯🇵Niigata, Japan
Okayama University Hospital
🇯🇵Okayama, Japan
Osaka International Cancer Institute
🇯🇵Osaka City, Japan
Hokkaido University Hospital
🇯🇵Sapporo-shi, Japan
Shizuoka Cancer Center
🇯🇵Shizuoka, Japan
The Cancer Institute Hospital of JFCR
🇯🇵Tokyo, Japan
Fujita Health University Hospital
🇯🇵Toyoake, Japan
National Hospital Organization Osaka Toneyama Medical Center
🇯🇵Toyonaka-shi, Japan
Wakayama Medical University Hospital
🇯🇵Wakayama, Japan
National Hospital Organization Iwakuni Clinical Center
🇯🇵Yamaguchi, Japan
National Hospital Organization Yamaguchi Ube Medical Center
🇯🇵Yamaguchi, Japan
National Cancer Center
🇰🇷Gyeonggi-do, Korea, Republic of
CHA Bundang Medical Center, CHA University
🇰🇷Gyeonggi-do, Korea, Republic of
GyeongSang National University Hospital
🇰🇷Gyeongsangnam-do, Korea, Republic of
Chonnam National University Hwasun Hospital
🇰🇷Jeollanam-do, Korea, Republic of
Seoul National University Bundang Hospital
🇰🇷Seongnam-si, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Severance Hospital Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Prince Court Medical Centre
🇲🇾Kuala Lumpur, Malaysia
Pantai Hospital Kuala Lumpur
🇲🇾Kuala Lumpur, Malaysia
University Malaya Medical Centre
🇲🇾Kuala Lumpur, Malaysia
Hospital Umum Sarawak
🇲🇾Kuching, Malaysia
Beacon Hospital Sdn Bhd
🇲🇾Petaling Jaya, Malaysia
Sunway Medical Centre
🇲🇾Petaling Jaya, Malaysia
Krakowski Szpital Specjalityczny im. Jana Pawla II
🇵🇱Krakow, Poland
Mazowieckie Centrum Leczenia Chorob Pluc
🇵🇱Otwock, Poland
Private Specialist Hospitals - MedPolonia
🇵🇱Poznan, Poland
Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
🇵🇱Warszawa, Poland
Hospital de Braga
🇵🇹Braga, Portugal
Hospital da Luz, SA
🇵🇹Lisboa, Portugal
Hosp. Cuf Descobertas
🇵🇹Lisboa, Portugal
Ulsm - Hosp. Pedro Hispano
🇵🇹Senhora da Hora, Portugal
Hosp Univ A Coruna
🇪🇸A Coruna, Spain
Hosp. Gral. Univ. de Alicante
🇪🇸Alicante, Spain
Hosp Univ Vall D Hebron
🇪🇸Barcelona, Spain
Hosp Clinic de Barcelona
🇪🇸Barcelona, Spain
Hosp. Univ. Quiron Dexeus
🇪🇸Barcelona, Spain
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
National Taiwan University Cancer Center
🇨🇳Taipei City, Taiwan
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Linkou Chang Gung Memorial Hospital
🇨🇳Taoyuan, Taiwan
Phramongkutklao Hospital and Medical College
🇹🇭Bangkok, Thailand
Siriraj Hospital
🇹🇭Bangkok, Thailand
Chiang Mai University
🇹🇭Chiangmai, Thailand
Adana City Hospital
🇹🇷Adana, Turkey
Adana Baskent Hospital
🇹🇷Adana, Turkey
Memorial Ankara Hastanesi
🇹🇷Ankara, Turkey
Gazi University Hospital
🇹🇷Ankara, Turkey
Ankara Bilkent City Hospital
🇹🇷Ankara, Turkey
Trakya University Medical Faculty
🇹🇷Edirne, Turkey
Istanbul University Cerrahpasa Medical Faculty
🇹🇷Istanbul, Turkey
Acıbadem Maslak Hospital
🇹🇷Istanbul, Turkey
Dokuz Eylul University Medical Faculty
🇹🇷Izmir, Turkey
IEU Medical Point Hospital
🇹🇷Izmir, Turkey
Medical Park Samsun Hastanesi
🇹🇷Samsun, Turkey
Birmingham Heartlands Hospital
🇬🇧Birmingham, United Kingdom
Imperial College Healthcare
🇬🇧London, United Kingdom
Newcastle Freeman Hospital
🇬🇧Newcastle Upon Tyne, United Kingdom
Royal Marsden Hospital
🇬🇧Sutton, United Kingdom